Antibody Information

General Information of This Antibody

Each Antibody-drug Conjugate Related to This Antibody

Full Information of The Activity Data of The ADC(s) Related to This Antibody

CLDN1 ADC [Investigative]

ADC Info

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 51.93% (Day 26)	Positive CLDN1 expression (CLDN1 +++/++)
Method Description	100,000 SW620 cells were suspended in culture medium and Matrigel (v/v) and injected subcutaneously into the right flank of 6-week-old female athymic nude mice. When the tumor volume reached approximately 100 mm³, mice were randomized in different groups. For ADC experiments, mice received by iv injection 0.9% NaCl or ADCs (5 mg/kg per injection) twice per week for 4 weeks. Click to Show/Hide
In Vivo Model	SW620 CDX model
In Vitro Model	Colon adenocarcinoma	SW620 cells		CVCL_0547
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 55.59% (Day 22)	Positive CLDN1 expression (CLDN1 +++/++)
Method Description	100,000 SW620 cells were suspended in culture medium and Matrigel (v/v) and injected subcutaneously into the right flank of 6-week-old female athymic nude mice. For the sequential combination experiments, mice received oxaliplatin at 3 mg/kg once per week followed by an iv injection of ADC-6F6 at 5 mg/kg after 3 and 6 days.
In Vivo Model	SW620 CDX model
In Vitro Model	Colon adenocarcinoma	SW620 cells		CVCL_0547

References

Ref 1	Improving the response to oxaliplatin by targeting chemotherapy-induced CLDN1 in resistant metastatic colorectal cancer cells. Cell Biosci. 2023 Apr 11;13(1):72. doi: 10.1186/s13578-023-01015-5.